EE9900452A - 4,4-Disubstituted-3,4-Dihydro-2 (1H) -quinazolinones useful as HIV reverse transcriptase inhibitors - Google Patents

4,4-Disubstituted-3,4-Dihydro-2 (1H) -quinazolinones useful as HIV reverse transcriptase inhibitors

Info

Publication number
EE9900452A
EE9900452A EEP199900452A EEP9900452A EE9900452A EE 9900452 A EE9900452 A EE 9900452A EE P199900452 A EEP199900452 A EE P199900452A EE P9900452 A EEP9900452 A EE P9900452A EE 9900452 A EE9900452 A EE 9900452A
Authority
EE
Estonia
Prior art keywords
disubstituted
dihydro
reverse transcriptase
transcriptase inhibitors
hiv reverse
Prior art date
Application number
EEP199900452A
Other languages
Estonian (et)
Inventor
W. Corbett Jeffrey
Sung Ko Soo
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE9900452A publication Critical patent/EE9900452A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP199900452A 1997-04-09 1998-04-07 4,4-Disubstituted-3,4-Dihydro-2 (1H) -quinazolinones useful as HIV reverse transcriptase inhibitors EE9900452A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US7132298P 1998-01-14 1998-01-14
PCT/US1998/006733 WO1998045276A2 (en) 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
EE9900452A true EE9900452A (en) 2000-04-17

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900452A EE9900452A (en) 1997-04-09 1998-04-07 4,4-Disubstituted-3,4-Dihydro-2 (1H) -quinazolinones useful as HIV reverse transcriptase inhibitors

Country Status (19)

Country Link
EP (1) EP0973753A2 (en)
JP (1) JP2002504095A (en)
KR (1) KR20010006146A (en)
CN (1) CN1252063A (en)
AR (1) AR012340A1 (en)
AU (1) AU734928B2 (en)
BR (1) BR9808513A (en)
CA (1) CA2284996A1 (en)
EA (1) EA001991B1 (en)
EE (1) EE9900452A (en)
HR (1) HRP980143A2 (en)
HU (1) HUP0001446A3 (en)
IL (1) IL132188A0 (en)
NO (1) NO314936B1 (en)
NZ (1) NZ500592A (en)
PL (1) PL336305A1 (en)
SK (1) SK137899A3 (en)
TW (1) TW587078B (en)
WO (1) WO1998045276A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068189A1 (en) * 1998-03-27 2001-01-17 Bristol-Myers Squibb Pharma Company 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
AU6508899A (en) 1998-10-13 2000-05-01 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
AU1821900A (en) * 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Process for the preparation of quinazolinones
BR9916750A (en) * 1998-11-19 2001-11-06 Du Pont Pharm Co Reverse transcriptase inhibiting compounds, pharmaceutical compositions, methods of treating infections by human immunodeficiency virus, processes for preparing the compound and its crystalline form
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
DE60023025T2 (en) 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-DIHYDRO- (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
EP1268447A2 (en) * 2000-03-23 2003-01-02 Bristol-Myers Squibb Pharma Company Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
US6555686B2 (en) * 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc METHOD AND APPARATUS FOR AN IMPROVED SAMPLING INTERFERENCE DEVICE
WO2005037095A1 (en) 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (en) * 2011-01-20 2011-05-18 天津大学 4-(substituted-1,3-diyne)-4-(trifluoromethyl)-3,4-dihydro substituted quinazoline-2-ketone compound as well as preparation method and application thereof
ES2606511T3 (en) * 2011-04-06 2017-03-24 Biovaxim Limited Pharmaceutical compositions to prevent and / or treat an HIV disease in humans
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
CN105209467B (en) 2013-05-27 2018-06-08 诺华股份有限公司 Imidazopyrrolidone derivatives and their use in the treatment of diseases
AU2014272695B2 (en) 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
WO2014191911A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
MX2016006667A (en) 2013-11-21 2016-07-26 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors.
CN116745269A (en) * 2020-08-27 2023-09-12 默沙东有限责任公司 Dihydroquinazolin-2-one derivatives as selective cytotoxic agents for the treatment of HIV
US20250026759A1 (en) * 2023-07-07 2025-01-23 Merck Sharp & Dohme Llc Tetrahydroquinazoline derivatives as selective cytotoxic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
KR950701322A (en) * 1992-05-07 1995-03-23 조셉 에프. 디프리마 New quinazolines as inhibitors of HIV reversetranscriptase as inhibitors of human immunodeficiency virus reverse transcriptase
US5663169A (en) * 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (en) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazoline derivatives and medicaments containing them
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
WO1998045276A3 (en) 1999-01-14
EA199900907A1 (en) 2000-04-24
EA001991B1 (en) 2001-10-22
SK137899A3 (en) 2000-05-16
AU6796098A (en) 1998-10-30
JP2002504095A (en) 2002-02-05
WO1998045276A2 (en) 1998-10-15
NO314936B1 (en) 2003-06-16
AU734928B2 (en) 2001-06-28
NO994904L (en) 1999-12-01
PL336305A1 (en) 2000-06-19
TW587078B (en) 2004-05-11
NO994904D0 (en) 1999-10-08
AR012340A1 (en) 2000-10-18
CA2284996A1 (en) 1998-10-15
EP0973753A2 (en) 2000-01-26
HUP0001446A2 (en) 2001-05-28
KR20010006146A (en) 2001-01-26
HRP980143A2 (en) 1999-02-28
NZ500592A (en) 2001-09-28
BR9808513A (en) 2000-05-23
CN1252063A (en) 2000-05-03
HUP0001446A3 (en) 2001-11-28
IL132188A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
NO994904L (en) 4,4-Disubstituted-3,4-dihydro-2 (1H) -quinazolinones useful as HIV reverse transcriptase inhibitors
DK0945443T3 (en) HIV inhibitory pyrimidine derivatives
DK1002795T3 (en) HIV replication-inhibiting pyrimidines
FI950508L (en) Benzoxazinones as HIV reverse transcriptase inhibitors
DK0977737T3 (en) CRF antagonistic quino- and quinazoline
DE122012000017I1 (en) Novel form of s-omeprazole.
ATE423776T1 (en) ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND THEIR USES
SG80631A1 (en) Inhibitors of hiv reverse transcriptase
EE200200275A (en) 2,4-Diaminopyrimidine compounds used as immunosuppressants
FI953954A0 (en) HIV reverse transcriptase inhibitors
ID24361A (en) COMPRESSOR TOOLS
ATE303388T1 (en) SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDOC1,2-AÖPYRIMIDINE-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO-C1,2-AÖPYRIMIDINE-5(1H)ONE DERIVATIVES
DE60008353D1 (en) HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE
AU4719699A (en) Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
ID21444A (en) DIMMING TOOL
ATE277912T1 (en) PYRIMIDINE-2,4,6-TRIONE AS A MATRIXMETALLOPROTEINASE INHIBITOR
AU3199099A (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
AU4698399A (en) 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
DE59910200D1 (en) Coolable component
ZA982339B (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors.
AU2003263838A1 (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazoliniones useful as hiv reverse transcriptase inhibitors
AU4719799A (en) Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
DK0944603T3 (en) Process for the preparation of 2-amino-2-imidazoline, guanidine and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives
AU5588400A (en) 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
DK0966464T3 (en) Substituted 2,4-diaminopyrimidines